Evaluation of a Series of Naphthamides as Potent, Orally Active Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitors

Matthew M. Weiss(Amgen (United States)), Roger Zanon(Amgen (United States)), David Bauer(Amgen (United States)), Michael Schrag(Amgen (United States)), Danlin Chen(Amgen (United States)), Julie Flynn(Amgen (United States)), Juan Estrada(Amgen (United States)), Douglas A. Whittington(Amgen (United States)), George Borg(Aalborg University), Andrew S. Tasker(Amgen (United States)), Jean-Christophe Harmange(Amgen (United States)), Anthony Polverino(Amgen (United States)), Deborah M. Choquette(Amgen (United States)), Tom DeMelfi(Amgen (United States)), Charlie Starnes(Amgen (United States)), Michele Potashman(Biogen (United States)), Russell F. Graceffa(Amgen (United States)), Phillip M. Roveto(Amgen (United States)), Shawn Harriman(Amgen (United States)), James Bready(Amgen (United States)), Alexander Long(Amgen (United States)), Vinod F. Patel(Guy's Hospital), Daniel S. La(Amgen (United States)), Nicholas Doerr(Amgen (United States)), Virginia Berry(Amgen (United States)), Kelly Regal(Amgen (United States)), Loren Berry(Amgen (United States)), Yohannes Teffera(Amgen (United States)), Angela Coxon(Amgen (United States)), Stephen A. Kaufman(Amgen (United States)), Sesha Neervannan(Amgen (United States))
Journal of Medicinal Chemistry
March 1, 2008
Cited by 34


Related Papers